Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-12-2021 | Obesity

Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?

Authors: Ehab Bakbak, Daniella C. Terenzi, Justin Z. Trac, Hwee Teoh, Adrian Quan, Stephen A. Glazer, Ori D. Rotstein, Mohammed Al-Omran, Subodh Verma, David A. Hess

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 4/2021

Abstract

Type 2 diabetes (T2D) and obesity represent entangled pandemics that accelerate the development of cardiovascular disease (CVD). Given the immense burden of CVD in society, non-invasive prevention and treatment strategies to promote cardiovascular health are desperately needed. During T2D and obesity, chronic dysglycemia and abnormal adiposity result in systemic oxidative stress and inflammation that deplete the vascular regenerative cell reservoir in the bone marrow that impairs blood vessel repair and exacerbates the penetrance of CVD co-morbidities. This novel translational paradigm, termed ‘regenerative cell exhaustion’ (RCE), can be detected as the depletion and dysfunction of hematopoietic and endothelial progenitor cell lineages in the peripheral blood of individuals with established T2D and/or obesity. The reversal of vascular RCE has been observed after administration of the sodium-glucose cotransporter-2 inhibitor (SGLT2i), empagliflozin, or after bariatric surgery for severe obesity. In this review, we explore emerging evidence that links improved dysglycemia to a reduction in systemic oxidative stress and recovery of circulating pro-vascular progenitor cell content required for blood vessel repair. Given that bariatric surgery consistently increases systemic glucagon-like-peptide 1 (GLP-1) release, we also focus on evidence that the use of GLP-1 receptor agonists (GLP-1RA) during obesity may act to inhibit the progression of systemic dysglycemia and adiposity, and indirectly reduce inflammation and oxidative stress, thereby limiting the impact of RCE. Therefore, therapeutic intervention with currently-available GLP-1RA may provide a less-invasive modality to reverse RCE, bolster vascular repair mechanisms, and improve cardiometabolic risk in individuals living with T2D and obesity.

Abnormal Adiposity:

the condition of being severely overweight or obese.

Advanced Glycation End Products (AGE):

Molecules formed by the non-enzymatic and irreversible reaction of reducing sugars and the amino group of a protein, lipid or nucleic acid. AGE levels are often elevated during hyperglycemia and contribute to chronic oxidative stress.

Aldehyde dehydrogenase (ALDH):

An intracellular enzyme that protects progenitor cells from oxidative stress and alkylating agents. As progenitor cells differentiate and mature, ALDH expression decreases.

Atherosclerosis:

an inflammatory disease of the arteries characterized by the deposition of plaques of fatty material on their inner walls.

Body-mass Index (BMI):

A measurement of an individuals’ weight in relation to their height. BMI is often used clinically to classify obesity and is defined as body mass divided by the square of an individual’s height [Kg/m2].

Diabesity:

A term used to describe the overlapping pathophysiology of diabetes and obesity. Although distinct metabolic conditions, diabetes and obesity share many common features such as increased systemic inflammation and oxidative stress.

Dipeptidyl Peptidase 4 (DPP4):

A ubiquitously expressed serum protease responsible for the N-terminal cleavage of bioactive substrates. Particularly, DPP4 is responsible for degradation of the incretin class of peptides such as GLP-1.

Endothelial Progenitor Cell (EPC):

As building blocks of new blood vessels, circulating EPC function facilitates vessel repair and are critical in the prevention of ischemic complications.

Glucagon-like Peptide 1 (GLP-1):

Belonging to the incretin family, this peptide hormone is secreted primarily by L-cells expressed throughout the gastrointestinal tract. GLP-1s primary function is to promote insulin secretion by β-cells, and inhibit glucagon secretion by α-cells of the pancreas.

Dysglycemia:

abnormality in blood glucose level stability.

Hematopoietic Progenitor Cell (HPC):

A multipotent cell line capable of differentiating into both myeloid, and lymphoid blood cell types. Their function is critical for promoting vessel repair and maintaining homeostasis..

Mesenchymal Progenitor Cell (MPC):

A multipotent cell line capable of differentiating into pericytes and smooth muscle cells. Once in the peripheral circulation, these cells envelop blood vessels, stabilize new capillaries and promote vascular integrity.

NOD-like Receptor, Pyrin Domain-containing 3 (NLRP3):

Expressed mostly in macrophages, this protein is a vital component of the NLRP3 inflammasome. Upon activation, the NLRP3 inflammasome catalyzes the activation of pro-inflammatory cytokines that modulate inflammation and apoptosis.

Reactive Oxygen Species (ROS):

A class of oxygen-containing, and highly reactive, free-radical produced as a product of mitochondrial oxidative phosphorylation. A buildup of ROS, characteristic of cardiometabolic disease, can result in cellular damage and promote systemic inflammation.

Regenerative Cell Exhaustion (RCE):

A state characterized by the depletion and dysfunction of pro-vascular progenitor cell, which ultimately results in decreased vessel repair. RCE is the result of chronic inflammation and oxidative stress and can be detected in the bone marrow of individuals with cardiometabolic disease.

Sodium Glucose Cotransporter-2 (SGLT2):

A transport protein found in the proximal tubule of the kidney. Inhibition of this transporter with pharmacological agents promotes glucose excretion, combatting hyperglycemia.

Type 2 Diabetes (T2D):

A metabolic condition characterized by glucotoxicity as a result of decreased insulin sensitivity and chronic hyperglycemia. T2D is an important risk factor for developing ischemic cardiovascular comorbidities.

Roth GA, Abate D, Abate KH, et al. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018;392:1736–88. https://doi.org/10.1016/S0140-6736(18)32203-7.CrossRef

Bramante CT, Lee CJ, Gudzune KA. Treatment of Obesity in Patients With Diabetes. Diabetes Spectr. 2017;30:237–43. https://doi.org/10.2337/ds17-0030.CrossRefPubMedPubMedCentral

Beckman JA, Paneni F, Cosentino F, Creager MA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: part II. Eur Heart J. 2013;34:2444–52. https://doi.org/10.1093/eurheartj/eht142.CrossRefPubMed

International Diabetes Federation. IDF Diabetes Atlas. (2019) 9th Edn.

Cho NH, Shaw JE, Karuranga S, et al. IDF Diabetes Atlas: Global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271–81. https://doi.org/10.1016/j.diabres.2018.02.023.CrossRefPubMed

Wright AK, Suarez-Ortegon MF, Read SH, et al. Risk Factor Control and Cardiovascular Event Risk in People With Type 2 Diabetes in Primary and Secondary Prevention Settings. Circulation. 2020;142:1925–36. https://doi.org/10.1161/CIRCULATIONAHA.120.046783.CrossRefPubMedPubMedCentral

Poirier P, Giles TD, Bray GA, et al. Obesity and cardiovascular disease: Pathophysiology, evaluation, and effect of weight loss: An update of the 1997 American Heart Association Scientific Statement on obesity and heart disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation. 2006;113:898–918.CrossRefPubMed

Wharton S, Lau DCW, Vallis M, et al. Obesity in adults: A clinical practice guideline. CMAJ. 2020;192:E875–91. https://doi.org/10.1503/cmaj.191707.CrossRefPubMedPubMedCentral

Kaptoge S, Pennells L, De Bacquer D, et al. World Health Organization cardiovascular disease risk charts: revised models to estimate risk in 21 global regions. Lancet Glob Heal. 2019;7:e1332–45. https://doi.org/10.1016/S2214-109X(19)30318-3.CrossRef

10.

Risk Factor Collaboration NCD, (NCD-RisC) L, Abdeen ZA, Hamid ZA, , et al. Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128·9 million children, adolescents, and adults. Lancet (London, England). 2017;390:2627–42. https://doi.org/10.1016/S0140-6736(17)32129-3.CrossRef

11.

Heymsfield SB, Gonzalez MCC, Shen W, et al. Weight loss composition is one-fourth fat-free mass: a critical review and critique of this widely cited rule. Obes Rev. 2014;15:310–21. https://doi.org/10.1111/obr.12143.CrossRefPubMedPubMedCentral

12.

Grant RW, Dixit VD. Adipose tissue as an immunological organ. Obesity. 2015;23:512–8. https://doi.org/10.1002/oby.21003.CrossRefPubMed

13.

Mechanick JI, Farkouh ME, Newman JD, Garvey WT. Cardiometabolic-Based Chronic Disease, Adiposity and Dysglycemia Drivers: JACC State-of-the-Art Review. J Am Coll Cardiol. 2020;75:525–38. https://doi.org/10.1016/j.jacc.2019.11.044.CrossRefPubMedPubMedCentral

14.

Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;80:275:964–967. https://doi.org/10.1126/science.275.5302.964

15.

Urbich C, Heeschen C, Aicher A, et al. Relevance of Monocytic Features for Neovascularization Capacity of Circulating Endothelial Progenitor Cells. Circulation. 2003;108:2511–6. https://doi.org/10.1161/01.CIR.0000096483.29777.50.CrossRefPubMed

16.

Yoder MC, Mead LE, Prater D, et al (2007) Redefining endothelial progenitor cells via clonal analysis and hematopoietic stem/progenitor cell principals. In: Blood. Blood, pp 1801–1809

17.

Qadura M, Terenzi DC, Verma S, et al. Concise Review: Cell Therapy for Critical Limb Ischemia: An Integrated Review of Preclinical and Clinical Studies. Stem Cells. 2018;36:161–71. https://doi.org/10.1002/stem.2751.CrossRefPubMed

18.

Crisan M, Yap S, Casteilla L, et al. A Perivascular Origin for Mesenchymal Stem Cells in Multiple Human Organs. Cell Stem Cell. 2008;3:301–13. https://doi.org/10.1016/j.stem.2008.07.003.CrossRefPubMed

19.

Fadini GP, Spinetti G, Santopaolo M, Madeddu P. Impaired regeneration contributes to poor outcomes in diabetic peripheral artery disease. Arterioscler Thromb Vasc Biol. 2020;40(1):34–44. https://www.ahajournals.org/doi/10.1161/ATVBAHA.119.312863

20.

Terenzi DC, Al-Omran M, Quan A, et al. Circulating Pro-Vascular Progenitor Cell Depletion During Type 2 Diabetes. JACC Basic to Transl Sci. 2019;4:98–112. https://doi.org/10.1016/j.jacbts.2018.10.005.CrossRef

21.

Fadini GP, Albiero M, De Kreutzenberg SV, et al. Diabetes impairs stem cell and proangiogenic cell mobilization in humans. Diabetes Care. 2013;36:943–9. https://doi.org/10.2337/dc12-1084.CrossRefPubMedPubMedCentral

22.

DiPersio JF. Diabetic Stem-Cell “Mobilopathy.” N Engl J Med. 2011;365:2536–8. https://doi.org/10.1056/nejmcibr1112347.CrossRefPubMed

23.

Albiero M, Ciciliot S, Tedesco S, et al. Diabetes-associated myelopoiesis drives stem cell mobilopathy through an OSM-p66Shc signaling pathway. Diabetes. 2019;68:1303–14. https://doi.org/10.2337/db19-0080.CrossRefPubMed

24.

Cappellari R, D’Anna M, Menegazzo L, et al. Diabetes mellitus impairs circulating proangiogenic granulocytes. Diabetologia. 2020;63:1872–84. https://doi.org/10.1007/s00125-020-05142-3.CrossRefPubMed

25.

Albiero M, Tedesco S, Amendolagine FI, et al. Inhibition of SGLT-2 rescues bone marrow cell traffic for vascular repair. Role of glucose control and ketogenesis. Diabetes. 2021. https://doi.org/10.2337/db20-1045.

26.

Capoccia BJ, Robson DL, Levac KD, et al. Revascularization of ischemic limbs after transplantation of human bone marrow cells with high aldehyde dehydrogenase activity. Blood. 2009;113:5340–51. https://doi.org/10.1182/blood-2008-04-154567.CrossRefPubMedPubMedCentral

27.

Hess DA, Meyerrose TE, Wirthlin L, et al. Functional characterization of highly purified human hematopoietic repopulating cells isolated according to aldehyde dehydrogenase activity. Blood. 2004;104. https://doi.org/10.1182/blood-2004-02-0448.

28.

Hess DA, Wirthlin L, Craft TP, et al. Selection based on CD133 and high aldehyde dehydrogenase activity isolates long-term reconstituting human hematopoietic stem cells. Blood. 2006;107:2162–9. https://doi.org/10.1182/blood-2005-06-2284.CrossRefPubMedPubMedCentral

29.

Putman DM, Liu KY, Broughton HC, et al. Umbilical Cord Blood-Derived Aldehyde Dehydrogenase-Expressing Progenitor Cells Promote Recovery from Acute Ischemic Injury. Stem Cells. 2012;30:2248–60. https://doi.org/10.1002/stem.1206.CrossRefPubMed

30.

Terenzi DC, Bakbak E, Trac JZ, et al. Isolation and characterization of circulating pro-vascular progenitor cell subsets from human whole blood samples. STAR Protoc. 2021;2: 100311. https://doi.org/10.1016/j.xpro.2021.100311.CrossRefPubMedPubMedCentral

31.

Putman DM, Cooper TT, Sherman SE, et al. Expansion of Umbilical Cord Blood Aldehyde Dehydrogenase Expressing Cells Generates Myeloid Progenitor Cells that Stimulate Limb Revascularization. Stem Cells Transl Med. 2017;6:1607–19. https://doi.org/10.1002/sctm.16-0472.CrossRefPubMedPubMedCentral

32.

Sherman SE, Kuljanin M, Cooper TT, et al. High Aldehyde Dehydrogenase Activity Identifies a Subset of Human Mesenchymal Stromal Cells with Vascular Regenerative Potential. Stem Cells. 2017;35:1542–53. https://doi.org/10.1002/stem.2612.CrossRefPubMed

33.

Fadini GP, Miorin M, Facco M, et al. Circulating Endothelial Progenitor Cells Are Reduced in Peripheral Vascular Complications of Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2005;45:1449–57.CrossRefPubMed

34.

Vasa M, Fichtlscherer S, Aicher A, et al. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res. 2001;89. https://doi.org/10.1161/hh1301.093953.

35.

Werner N, Kosiol S, Schiegl T, et al. Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. N Engl J Med. 2005;353:999–1007. https://doi.org/10.1056/NEJMoa043814.CrossRefPubMed

36.

Ahmed FW, Rider R, Glanville M, et al. Metformin improves circulating endothelial cells and endothelial progenitor cells in type 1 diabetes: MERIT study. Cardiovasc Diabetol. 2016;15:1–10. https://doi.org/10.1186/s12933-016-0413-6.CrossRef

37.

Yu JW, Deng YP, Han X, et al. Metformin improves the angiogenic functions of endothelial progenitor cells via activating AMPK/eNOS pathway in diabetic mice. Cardiovasc Diabetol. 2016;15:1–10. https://doi.org/10.1186/s12933-016-0408-3.CrossRef

38.

Xu G, Wu H, Zhang J, et al. Metformin ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice. Free Radic Biol Med. 2015;87:15–25. https://doi.org/10.1016/j.freeradbiomed.2015.05.045.CrossRefPubMedPubMedCentral

39.

Bakhashab S, Ahmed FW, Schulten HJ, et al. Metformin improves the angiogenic potential of human CD34+ cells co-incident with downregulating CXCL10 and TIMP1 gene expression and increasing VEGFA under hyperglycemia and hypoxia within a therapeutic window for myocardial infarction. Cardiovasc Diabetol. 2016;15:27. https://doi.org/10.1186/s12933-016-0344-2.CrossRefPubMedPubMedCentral

40.

Hess DA, Terenzi DC, Trac JZ, et al. SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus. Cell Metab. 2019;30:609–13. https://doi.org/10.1016/j.cmet.2019.08.015.CrossRefPubMed

41.

Lupoli R, Di Minno MND, Guidone C, et al. Effects of bariatric surgery on markers of subclinical atherosclerosis and endothelial function: a meta-analysis of literature studies. Int J Obes. 2016;40:395–402. https://doi.org/10.1038/ijo.2015.187.CrossRef

42.

Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: A joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77. https://doi.org/10.2337/dc16-0236.CrossRefPubMed

43.

Gadde KM, Martin CK, Berthoud H-R, Heymsfield SB. Obesity - Pathophysiology and Management. J Am Coll Cardiol. 2018;71:69–84. https://doi.org/10.1016/j.jacc.2017.11.011.CrossRefPubMedPubMedCentral

44.

Heymsfield SB, Wadden TA. Mechanisms, Pathophysiology, and Management of Obesity. N Engl J Med. 2017;376:254–66. https://doi.org/10.1056/NEJMra1514009.CrossRefPubMed

45.

Buchwald H, Oien DM. Metabolic/Bariatric Surgery Worldwide 2011. Obes Surg. 2013;23:427–36. https://doi.org/10.1007/s11695-012-0864-0.CrossRefPubMed

46.

Khorgami Z, Shoar S, Andalib A, et al. Trends in Utilization of Bariatric Surgery, 2010-2014: Sleeve Gastrectomy Dominates. Surg Obes Relat Dis. 2017;13. https://doi.org/10.1016/J.SOARD.2017.01.031.

47.

Welbourn R, Hollyman M, Kinsman R, et al. Bariatric Surgery Worldwide: Baseline Demographic Description and One-Year Outcomes from the Fourth IFSO Global Registry Report 2018. Obes Surg. 2019;29:782–95. https://doi.org/10.1007/s11695-018-3593-1.CrossRefPubMed

48.

Gloy VL, Briel M, Bhatt DL, et al. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. BMJ. 2013;347: f5934. https://doi.org/10.1136/bmj.f5934.CrossRefPubMedPubMedCentral

49.

Khera R, Murad MH, Chandar AK, et al. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016;315:2424–34. https://doi.org/10.1001/jama.2016.7602.CrossRefPubMedPubMedCentral

50.

Mingrone G, Panunzi S, De Gaetano A, et al. Metabolic surgery versus conventional medical therapy in patients with type 2 diabetes: 10-year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2021;397:293–304. https://doi.org/10.1016/S0140-6736(20)32649-0.CrossRefPubMed

51.

Buchwald H, Estok R, Fahrbach K, et al. Weight and Type 2 Diabetes after Bariatric Surgery: Systematic Review and Meta-analysis. Am J Med. 2009;122:248-256.e5. https://doi.org/10.1016/J.AMJMED.2008.09.041.CrossRefPubMed

52.

Pories WJ, Swanson MS, MacDonald KG, et al. Who would have thought it? An operation proves to be the most effective therapy for adult-onset diabetes mellitus. Ann Surg. 1995;222:332–9. https://doi.org/10.1097/00000658-199509000-00011.CrossRef

53.

Carlsson LMS, Sjöholm K, Jacobson P, et al. Life Expectancy after Bariatric Surgery in the Swedish Obese Subjects Study. N Engl J Med. 2020;383:1535–43. https://doi.org/10.1056/nejmoa2002449.CrossRefPubMedPubMedCentral

54.

Vest AR, Heneghan HM, Agarwal S, et al. Bariatric surgery and cardiovascular outcomes: a systematic review. Heart. 2012;98:1763–77. https://doi.org/10.1136/HEARTJNL-2012-301778.CrossRefPubMed

55.

Aminian A, Zajichek A, Arterburn DE, et al. Association of Metabolic Surgery with Major Adverse Cardiovascular Outcomes in Patients with Type 2 Diabetes and Obesity. In: JAMA - Journal of the American Medical Association. Am Med Assoc. 2019;1271–1282.

56.

Schauer PR, Bhatt DL, Kirwan JP, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes — 5-Year Outcomes. N Engl J Med. 2017;376:641–51. https://doi.org/10.1056/NEJMoa1600869.CrossRefPubMedPubMedCentral

57.

Xia Q, Campbell JA, Ahmad H, et al. Bariatric surgery is a cost‐saving treatment for obesity—A comprehensive meta‐analysis and updated systematic review of health economic evaluations of bariatric surgery. Obes Rev. 2020;21. https://doi.org/10.1111/obr.12932.

58.

Hess DA, Trac JZ, Glazer SA, et al. Vascular Risk Reduction in Obesity through Reduced Granulocyte Burden and Improved Angiogenic Monocyte Content following Bariatric Surgery. Cell Reports Med. 2020;1:100018.

59.

Yoshino M, Kayser BD, Yoshino J, et al. Effects of Diet versus Gastric Bypass on Metabolic Function in Diabetes. N Engl J Med. 2020;383:721–32. https://doi.org/10.1056/nejmoa2003697.CrossRefPubMedPubMedCentral

60.

Manning S, Pucci A, Batterham RL. GLP-1: A Mediator of the Beneficial Metabolic Effects of Bariatric Surgery? Physiology. 2015;30:50–62. https://doi.org/10.1152/physiol.00027.2014.CrossRefPubMed

61.

Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004;240:236–42. https://doi.org/10.1097/01.sla.0000133117.12646.48.CrossRefPubMedPubMedCentral

62.

Thaler JP, Cummings DE. Hormonal and Metabolic Mechanisms of Diabetes Remission after Gastrointestinal Surgery. Endocrinology. 2009;150:2518–25. https://doi.org/10.1210/en.2009-0367.CrossRefPubMed

63.

Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84:3434–8. https://doi.org/10.1073/pnas.84.10.3434.CrossRefPubMedPubMedCentral

64.

Pyke C, Heller RS, Kirk RK, et al. GLP-1 receptor localization in monkey and human tissue: Novel distribution revealed with extensively validated monoclonal antibody. Endocrinology. 2014;155:1280–90. https://doi.org/10.1210/en.2013-1934.CrossRefPubMed

65.

Shibasaki T, Takahashi H, Miki T, et al. Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP. Proc Natl Acad Sci U S A. 2007;104:19333–8. https://doi.org/10.1073/pnas.0707054104.CrossRefPubMedPubMedCentral

66.

Yusta B, Baggio LL, Koehler J, et al. GLP-1R agonists modulate enteric immune responses through the intestinal intraepithelial lymphocyte GLP-1R. Diabetes. 2015;64:2537–49. https://doi.org/10.2337/db14-1577.CrossRefPubMed

67.

Perez-Montes De Oca A, Pellitero S, Puig-Domingo M. Obesity and GLP-1. Minerva Endocrinol. 2020. https://doi.org/10.23736/S0391-1977.20.03369-6.

68.

Madsen MSA, Holm JB, Pallejà A, et al. Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice. Sci Rep. 2019;9:1–12. https://doi.org/10.1038/s41598-019-52103-x.CrossRef

69.

Laferrère B, Teixeira J, McGinty J, et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab. 2008;93:2479–85. https://doi.org/10.1210/jc.2007-2851.CrossRefPubMedPubMedCentral

70.

Jirapinyo P, Jin DX, Qazi T, et al. A Meta-Analysis of GLP-1 After Roux-En-Y Gastric Bypass: Impact of Surgical Technique and Measurement Strategy. Obes Surg. 2018;28:615–26. https://doi.org/10.1007/s11695-017-2913-1.CrossRefPubMed

71.

Larraufie P, Roberts GP, McGavigan AK, et al. Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery. Cell Rep. 2019;26:1399-1408.e6. https://doi.org/10.1016/j.celrep.2019.01.047.CrossRefPubMedPubMedCentral

72.

Ribeiro-Parenti L, Jarry AC, Cavin JB, et al. Bariatric surgery induces a new gastric mucosa phenotype with increased functional glucagon-like peptide-1 expressing cells. Nat Commun. 2021;12:1–11. https://doi.org/10.1038/s41467-020-20301-1.CrossRef

73.

Husain M, Birkenfeld AL, Donsmark M, et al. Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2019;381:841–51. https://doi.org/10.1056/NEJMoa1901118.CrossRefPubMed

74.

Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Discov. 2020;19:277–89. https://doi.org/10.1038/s41573-019-0053-0.CrossRefPubMed

75.

Campbell JE, Drucker DJ. Pharmacology, physiology, and mechanisms of incretin hormone action. Cell Metab. 2013;17:819–37.CrossRefPubMed

76.

Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27:740–56.CrossRefPubMed

77.

Lipscombe L, Booth G, Butalia S, et al. In Vitro Evaluation of Hypoglycemic Agents to Target Human Islet Amyloid Polypeptide: A Key Protein Involved in Amyloid Deposition and Beta-Cell Loss. Can J Diabetes. 2015. https://doi.org/10.1016/j.jcjd.2017.10.034.CrossRefPubMed

78.

Lovshin JA. Glucagon-like Peptide-1 Receptor Agonists: A Class Update for Treating Type 2 Diabetes. Can J diabetes. 2017;41:524–35. https://doi.org/10.1016/j.jcjd.2017.08.242.CrossRefPubMed

79.

Varin EM, McLean BA, Lovshin JA. Glucagon-Like Peptide-1 Receptor Agonists in Type 2 Diabetes: Review of Cardiovascular Outcome Trials. Can J Diabetes. 2019. https://doi.org/10.1016/j.jcjd.2019.08.011.CrossRefPubMed

80.

Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med NEJMoa2032183; 2021. https://doi.org/10.1056/NEJMoa2032183.

81.

Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397:971–84. https://doi.org/10.1016/S0140-6736(21)00213-0.CrossRefPubMed

82.

Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N Engl J Med. 2015;373:11–22. https://doi.org/10.1056/NEJMoa1411892.CrossRefPubMed

83.

Ryan DH, Lingvay I, Colhoun HM, et al. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. Am Heart J. 2020;229:61–9. https://doi.org/10.1016/j.ahj.2020.07.008.CrossRefPubMed

84.

Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015;373:2247–57. https://doi.org/10.1056/NEJMoa1509225.CrossRefPubMed

85.

Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2016;375:311–22. https://doi.org/10.1056/NEJMoa1603827.CrossRefPubMedPubMedCentral

86.

Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016;375:1834–44. https://doi.org/10.1056/NEJMoa1607141.CrossRefPubMed

87.

Holman RR, Bethel MA, Mentz RJ, et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2017;377:1228–39. https://doi.org/10.1056/NEJMoa1612917.CrossRefPubMed

88.

Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet. 2018;392:1519–29. https://doi.org/10.1016/S0140-6736(18)32261-X.CrossRefPubMed

89.

Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394:121–30. https://doi.org/10.1016/S0140-6736(19)31149-3.CrossRefPubMed

90.

MacDonald PE, El-kholy W, Riedel MJ, et al. The multiple actions of GLP-1 on the process of glucose-stimulated insulin secretion. In: Diabetes. American Diabetes Association Inc., 2002;S434–S442.

91.

Dickson SL, Shirazi RH, Hansson C, et al. The glucagon-like peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding value of food: A new role for mesolimbic GLP-1 receptors. J Neurosci. 2012;32:4812–20. https://doi.org/10.1523/JNEUROSCI.6326-11.2012.CrossRefPubMedPubMedCentral

92.

van Bloemendaal L, ten Kulve JS, La Fleur SE, et al. Effects of glucagon-like peptide 1 on appetite and body weight: Focus on the CNS. J Endocrinol. 2014;221:1–16. https://doi.org/10.1530/JOE-13-0414.CrossRef

93.

Cabou C, Vachoux C, Campistron G, et al. Brain GLP-1 signaling regulates femoral artery blood flow and insulin sensitivity through hypothalamic PKC-δ. Diabetes. 2011;60:2245–56. https://doi.org/10.2337/db11-0464.CrossRefPubMedPubMedCentral

94.

Hogan AE, Tobin AM, Ahern T, et al. Glucagon-like peptide-1 (GLP-1) and the regulation of human invariant natural killer T cells: Lessons from obesity, diabetes and psoriasis. Diabetologia. 2011;54:2745–54. https://doi.org/10.1007/s00125-011-2232-3.CrossRefPubMedPubMedCentral

95.

Hogan AE, Gaoatswe G, Lynch L, et al. Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia. 2014;57:781–4. https://doi.org/10.1007/s00125-013-3145-0.CrossRefPubMed

96.

Yusta B, Baggio LL, Koehler J, et al. GLP-1R Agonists Modulate Enteric Immune Responses Through the Intestinal Intraepithelial Lymphocyte GLP-1R. 2015. https://doi.org/10.2337/db14-1577.

97.

Zhu E, Hu L, Wu H, et al. Dipeptidyl peptidase-4 regulates hematopoietic stem cell activation in response to chronic stress. J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.117.006394.

98.

Sanz C, Vázquez P, Blázquez C, et al. Signaling and biological effects of glucagon-like peptide 1 on the differentiation of mesenchymal stem cells from human bone marrow. Am J Physiol Endocrinol Metab. 2010;298. https://doi.org/10.1152/ajpendo.00460.2009.

99.

Zhou H, Li D, Shi C, et al. Effects of Exendin-4 on bone marrow mesenchymal stem cell proliferation, migration and apoptosis in vitro. Sci Rep. 2015;5:12898. https://doi.org/10.1038/srep12898.CrossRefPubMedPubMedCentral

100.

Challa TD, Beaton N, Arnold M, et al. Regulation of adipocyte formation by GLP-1/GLP-1R signaling. J Biol Chem. 2012;287:6421–30. https://doi.org/10.1074/jbc.M111.310342.CrossRefPubMed

101.

Wang X, Chen J, Rong C, et al. GLP-1RA promotes brown adipogenesis of C3H10T1/2 mesenchymal stem cells via the PI3K-AKT-mTOR signaling pathway. Biochem Biophys Res Commun. 2018;506:976–82. https://doi.org/10.1016/j.bbrc.2018.10.197.CrossRefPubMed

102.

Saely CH, Geiger K, Drexel H. Brown versus white adipose tissue: A mini-review. Gerontology. 2011;58:15–23.CrossRef

103.

Kooijman S, Wang Y, Parlevliet ET, et al. Central GLP-1 receptor signalling accelerates plasma clearance of triacylglycerol and glucose by activating brown adipose tissue in mice. Diabetologia. 2015;58:2637–46. https://doi.org/10.1007/s00125-015-3727-0.CrossRefPubMedPubMedCentral

104.

Luo G, Liu H, Lu H. Glucagon-like peptide-1(GLP-1) receptor agonists: Potential to reduce fracture risk in diabetic patients? Br J Clin Pharmacol. 2016;81:78–88.CrossRefPubMed

105.

Xie XY, Mo ZH, Chen K, et al. Glucagon-like peptide-1 improves proliferation and differentiation of endothelial progenitor cells via upregulating VEGF generation. Med Sci Monit. 2011;17:BR35. https://doi.org/10.12659/msm.881383.

106.

Aronis KN, Tsoukas MA, Mantrzoros CS. Potential cardioprotective action of GLP-1: from bench to bedside. Metabolism. 2014;63:979–88. https://doi.org/10.1016/j.metabol.2014.05.009.CrossRefPubMed

107.

Di Y, He J, Ma P, et al. Liraglutide promotes the angiogenic ability of human umbilical vein endothelial cells through the JAK2/STAT3 signaling pathway. Biochem Biophys Res Commun. 2020;523:666–71. https://doi.org/10.1016/j.bbrc.2020.01.004.CrossRefPubMed

108.

Zhan Y, Sun H lin, Chen H, et al. Glucagon-like peptide-1 (GLP-1) protects vascular endothelial cells against advanced glycation end products (AGEs) - induced apoptosis. Med Sci Monit. 2016;18:BR286. https://doi.org/10.12659/MSM.883207.

109.

Liu C, Liu Y, He J, et al. Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury. Front Pharmacol. 2019;10. https://doi.org/10.3389/fphar.2019.00789.

110.

Hill JM, Zalos G, Halcox JPJ, et al. Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk. N Engl J Med. 2003;348:593–600. https://doi.org/10.1056/nejmoa022287.CrossRefPubMed

111.

Fadini GP, Sartore S, Schiavon M, et al. Diabetes impairs progenitor cell mobilisation after hindlimb ischaemia-reperfusion injury in rats. Diabetologia. 2006;49:3075–84. https://doi.org/10.1007/s00125-006-0401-6.CrossRefPubMed

112.

Fadini GP, Bonora BM, Marcuzzo G, et al. Circulating Stem Cells Associate With Adiposity and Future Metabolic Deterioration in Healthy Subjects. J Clin Endocrinol Metab. 2015;100:4570–8. https://doi.org/10.1210/jc.2015-2867.CrossRefPubMed

113.

Fadini G, de Kreutzenberg S, Coracina A, et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. Eur Heart J. 2006;27:2247–55.CrossRefPubMed

114.

Timmermans M, Topal B, E Sanches E, et al. The effects of Glucagon Like Peptide-1 (GLP-1) on cardiac remodelling: exploring the role of medication and physiological modulation after metabolic surgery: a narrative review. Minerva Endocrinol. 2021. https://doi.org/10.23736/S2724-6507.21.03296-X.

115.

Giaccari A, Sorice G, Muscogiuri G. Glucose toxicity: The leading actor in the pathogenesis and clinical history of type 2 diabetes – mechanisms and potentials for treatment. Nutr Metab Cardiovasc Dis. 2009;19:365–77. https://doi.org/10.1016/j.numecd.2009.03.018.CrossRefPubMed

116.

Maedler K, Sergeev P, Ris F, et al. Glucose-induced β cell production of IL-1β contributes to glucotoxicity in human pancreatic islets. J Clin Invest. 2002;110:851–60. https://doi.org/10.1172/jci15318.CrossRefPubMedPubMedCentral

117.

Schauer PR, Mingrone G, Ikramuddin S, Wolfe B. Clinical outcomes of metabolic surgery: Efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39:902–11. https://doi.org/10.2337/dc16-0382.CrossRefPubMedPubMedCentral

118.

Andreadis P, Karagiannis T, Malandris K, et al. Semaglutide for type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes, Obes Metab. 2018;20:2255–63. https://doi.org/10.1111/dom.13361.CrossRef

119.

Buteau J, Roduit R, Susini S, Prentki M. Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)- cells. Diabetologia. 1999;42:856–64. https://doi.org/10.1007/s001250051238.CrossRefPubMed

120.

Imai Y, Dobrian AD, Weaver JR, et al. Interaction between cytokines and inflammatory cells in islet dysfunction, insulin resistance and vascular disease. Diabetes, Obes Metab. 2013;15:117–29. https://doi.org/10.1111/dom.12161.CrossRef

121.

Pugazhenthi U, Velmurugan K, Tran A, et al. Anti-inflammatory action of exendin-4 in human islets is enhanced by phosphodiesterase inhibitors: Potential therapeutic benefits in diabetic patients. Diabetologia. 2010;53:2357–68. https://doi.org/10.1007/s00125-010-1849-y.CrossRefPubMed

122.

Toso C, McCall M, Emamaullee J, et al. Liraglutide, a long-acting human glucagon-like peptide 1 analogue, improves human islet survival in culture. Transpl Int. 2010;23:259–65. https://doi.org/10.1111/j.1432-2277.2009.00984.x.CrossRefPubMed

123.

Stoffers DA, Kieffer TJ, Hussain MA, et al. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes. 2000;49:741–8. https://doi.org/10.2337/diabetes.49.5.741.CrossRefPubMed

124.

De Leó DD, Deng S, Madani R, et al. Role of Endogenous Glucagon-Like Peptide-1 in Islet Regeneration After Partial Pancreatectomy. 2003.

125.

Drucker DJ. Glucagon-Like Peptide-1 and the Islet β-Cell: Augmentation of Cell Proliferation and Inhibition of Apoptosis. Endocrinology. 2003;144:5145–8. https://doi.org/10.1210/en.2003-1147.CrossRefPubMed

126.

Jones AG, McDonald TJ, Shields BM, et al. Markers of β-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care. 2016;39:250–7. https://doi.org/10.2337/dc15-0258.CrossRefPubMed

127.

Zhang WQ, Tian Y, Chen XM, et al. Liraglutide ameliorates beta-cell function, alleviates oxidative stress and inhibits low grade inflammation in young patients with new-onset type 2 diabetes chiCTR1800018008 chiCTR. Diabetol Metab Syndr. 2018;10:91. https://doi.org/10.1186/s13098-018-0392-8.CrossRefPubMedPubMedCentral

128.

Tamura K, Minami K, Kudo M, et al. Liraglutide improves pancreatic beta cell mass and function in alloxan-induced diabetic mice. PLoS ONE. 2015;10: e0126003. https://doi.org/10.1371/journal.pone.0126003.CrossRefPubMedPubMedCentral

129.

Adam M, Murugavel S, Bugyei-Twum A, et al. BRCA2 is a Novel Regulator of Endothelial Cell Function and Apoptosis Following Oxidative Stress. Atheroscler Suppl. 2018;32:110. https://doi.org/10.1016/j.atherosclerosissup.2018.04.338.CrossRef

130.

Verma S, Anderson TJ. Fundamentals of endothelial function for the clinical cardiologist. Circulation. 2002;105:546–9.CrossRefPubMed

131.

Harrison DG. Cellular and molecular mechanisms of endothelial cell dysfunction. J Clin Invest. 1997;100:2153–7.CrossRefPubMedCentralPubMed

132.

Sledzinski T, Sledzinski M, Smolenski RT, Swierczynski J. Increased serum nitric oxide concentration after bariatric surgery-a potential mechanism for cardiovascular benefit. Obes Surg. 2010;20:204–10. https://doi.org/10.1007/s11695-009-0041-2.CrossRefPubMed

133.

Wei R, Ma S, Wang C, et al. Exenatide exerts direct protective effects on endothelial cells through the AMPK/Akt/eNOS pathway in a GLP-1 receptor-dependent manner. Am J Physiol Metab. 2016;310:E947–57. https://doi.org/10.1152/ajpendo.00400.2015.CrossRef

134.

Uribarri J, Cai W, Woodward M, et al. Elevated Serum Advanced Glycation Endproducts in Obese Indicate Risk for the Metabolic Syndrome: A Link Between Healthy and Unhealthy Obesity? J Clin Endocrinol Metab. 2015;100:1957–66. https://doi.org/10.1210/jc.2014-3925.CrossRefPubMedPubMedCentral

135.

Vinué Á, Navarro J, Herrero-Cervera A, et al. The GLP-1 analogue lixisenatide decreases atherosclerosis in insulin-resistant mice by modulating macrophage phenotype. Diabetologia. 2017;60:1801–12. https://doi.org/10.1007/s00125-017-4330-3.CrossRefPubMed

136.

Choe SS, Huh JY, Hwang IJ, et al. Adipose tissue remodeling: Its role in energy metabolism and metabolic disorders. Front. Endocrinol. (Lausanne). 2016;7:1.

137.

Elgazar-Carmon V, Rudich A, Hadad N, Levy R. Neutrophils transiently infiltrate intra-abdominal fat early in the course of high-fat feeding. J Lipid Res. 2008;49:1894–903. https://doi.org/10.1194/jlr.M800132-JLR200.CrossRefPubMed

138.

Nishimura S, Manabe I, Nagasaki M, et al. CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med. 2009;15:914–20. https://doi.org/10.1038/nm.1964.CrossRefPubMed

139.

Winer DA, Winer S, Shen L, et al. B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies. Nat Med. 2011;17:610–7. https://doi.org/10.1038/nm.2353.CrossRefPubMedPubMedCentral

140.

Rocha VZ, Folco EJ, Sukhova G, et al. Interferon-γ, a Th1 cytokine, regulates fat inflammation: A role for adaptive immunity in obesity. Circ Res. 2008;103:467–76. https://doi.org/10.1161/CIRCRESAHA.108.177105.CrossRefPubMedPubMedCentral

141.

Huh JY, Park YJ, Ham M, Kim JB. Crosstalk between adipocytes and immune cells in adipose tissue inflammation and metabolic dysregulation in obesity. Mol Cells. 2014;37:365–71.CrossRefPubMedCentralPubMed

142.

Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117:175–84. https://doi.org/10.1172/JCI29881.CrossRefPubMedPubMedCentral

143.

Verma S, Kuliszewski MA, Li SH, et al. C-Reactive Protein Attenuates Endothelial Progenitor Cell Survival, Differentiation, and Function: Further Evidence of a Mechanistic Link between C-Reactive Protein and Cardiovascular Disease. Circulation. 2004;109:2058–67. https://doi.org/10.1161/01.CIR.0000127577.63323.24.CrossRefPubMed

144.

Hein TW, Singh U, Vasquez-Vivar J, et al. Human C-reactive protein induces endothelial dysfunction and uncoupling of eNOS in vivo. Atherosclerosis. 2009;206:61–8. https://doi.org/10.1016/j.atherosclerosis.2009.02.002.CrossRefPubMedPubMedCentral

145.

Illán Gómez F, Gonzálvez Ortega M, Aragón Alonso A, et al. Obesity, endothelial function and inflammation: the effects of weight loss after bariatric surgery. Nutr Hosp. 2016;33:1340–1346. https://doi.org/10.20960/nh.793.

146.

Mocanu AO, Mulya A, Huang H, et al. Effect of roux-en-y gastric bypass on the NLRP3 Inflammasome in adipose tissue from obese rats. PLoS One. 2015;10. https://doi.org/10.1371/journal.pone.0139764.

147.

Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011;17:179–89. https://doi.org/10.1038/nm.2279.CrossRefPubMedPubMedCentral

148.

Chen A, Chen Z, Xia Y, et al. Liraglutide attenuates NLRP3 inflammasome-dependent pyroptosis via regulating SIRT1/NOX4/ROS pathway in H9c2 cells. Biochem Biophys Res Commun. 2018;499:267–72. https://doi.org/10.1016/j.bbrc.2018.03.142.CrossRefPubMed

149.

Luo X, Hu Y, He S, et al. Dulaglutide inhibits high glucose- induced endothelial dysfunction and NLRP3 inflammasome activation. Arch Biochem Biophys. 2019;671:203–9. https://doi.org/10.1016/j.abb.2019.07.008.CrossRefPubMed

150.

Mazidi M, Karimi E, Rezaie P, Ferns GA. Treatment with GLP1 receptor agonists reduce serum CRP concentrations in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. J. Diabetes Complications. 2017.

151.

Bian F, Yang XY, Xu G, et al. CRP-Induced NLRP3 Inflammasome Activation Increases LDL Transcytosis Across Endothelial Cells. Front Pharmacol 10.https://doi.org/10.3389/fphar.2019.00040.

152.

Lee YS, Jun HS. Anti-Inflammatory Effects of GLP-1-Based Therapies beyond Glucose Control. Mediators Inflamm. 2016.

153.

Zhang W, Huang Q, Zeng Z, et al. Sirt1 Inhibits Oxidative Stress in Vascular Endothelial Cells Oxid Med Cell Longev. 2017.

Title: Lessons from bariatric surgery: Can increased GLP-1 enhance vascular repair during cardiometabolic-based chronic disease?
Authors: Ehab Bakbak
Daniella C. Terenzi
Justin Z. Trac
Hwee Teoh
Adrian Quan
Stephen A. Glazer
Ori D. Rotstein
Mohammed Al-Omran
Subodh Verma
David A. Hess
Publication date: 01-12-2021
Publisher: Springer US
Keywords: Obesity
Obesity
Bariatric Surgery
Bariatric Surgery
Incretin Mimetics
Incretin Mimetics
Type 2 Diabetes
Semaglutide
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 4/2021
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-021-09669-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Paediatric Cushing’s disease: Epidemiology, pathogenesis, clinical management and outcome

Ectopic Cushing’s syndrome due to thymic neuroendocrine tumours: a systematic review

Glucocorticoid excess and COVID-19 disease

Therapeutic potentials of agonist and antagonist of adenosine receptors in type 2 diabetes

Skeletal abnormalities in Hypoparathyroidism and in Primary Hyperparathyroidism

Expected and paradoxical effects of obesity on cancer treatment response

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage